GPCR
Structure Therapeutics Inc - ADR

1,947
Mkt Cap
$4.91B
Volume
1.02M
52W High
$94.90
52W Low
$13.22
PE Ratio
-19.04
GPCR Fundamentals
Price
$69.55
Prev Close
$67.78
Open
$67.70
50D MA
$44.29
Beta
1.03
Avg. Volume
1.25M
EPS (Annual)
-$2.33
P/B
5.48
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are presently covering the stock...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3% - Here's Why
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3% - Here's Why...
MarketBeat·8d ago
News Placeholder
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.
Zacks·8d ago
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2% - Here's Why
Structure Therapeutics (NASDAQ:GPCR) Shares Up 5.2% - Time to Buy...
MarketBeat·9d ago
News Placeholder
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
Zacks·9d ago
News Placeholder
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Zacks·10d ago
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Still a Buy?
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Here's What Happened...
MarketBeat·13d ago
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.5% - Should You Sell?
Structure Therapeutics (NASDAQ:GPCR) Shares Down 8.5% - Here's Why...
MarketBeat·16d ago
News Placeholder
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Zacks·17d ago
News Placeholder
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR
Bellevue Group AG lifted its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 57.2% during the second quarter, according to the company in its most recent 13F filing...
MarketBeat·19d ago
<
1
2
...
>

Latest GPCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.